Related Experiment Video
Updated: Apr 26, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.2K
[Hepatitis B infection in children].
Vibeke Brix Christensen1, Sannie Nordly, Mette Kjær
1Gl. Strandvej 164, 3050 Humlebæk. brixchr@dadlnet.dk.
Ugeskrift for Laeger
|August 7, 2014
Summary
Chronic hepatitis B (HBV) affects 400 million globally, often acquired in childhood. Treatment is considered during immune activation phases, not the initial immune-tolerant stage, to prevent liver damage.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection impacts 400 million individuals worldwide.
- Transmission occurs through infected blood, body fluids, and vertically from mother to child.
- Hepatitis B infection in early life frequently leads to chronic infection, often starting in an immune-tolerant phase.
Purpose of the Study:
- To outline the natural history of chronic hepatitis B infection in children.
- To define the phases of chronic HBV infection relevant to treatment decisions.
- To highlight the potential long-term complications of untreated chronic HBV.
Main Methods:
- Review of epidemiological data on HBV prevalence and transmission.
- Description of the immunological phases of chronic HBV infection.
- Summary of current treatment options including interferon and nucleotide analogues.
Main Results:
- Most children infected early in life enter an immune-tolerant phase with no immediate need for antiviral therapy.
- Antiviral treatment becomes a consideration during the immune activation phase of chronic HBV.
- Hepatitis B infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma.
Conclusions:
- Understanding the distinct phases of chronic HBV infection is crucial for appropriate patient management.
- Timely intervention during immune activation can mitigate the risk of severe liver disease.
- Effective vaccination strategies remain a cornerstone in controlling the global burden of HBV.
Related Concept Videos
01:25Hepatitis
78
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
01:28Viral Hepatitis I: Introduction
18
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
18
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
405
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
01:27Cytomegalovirus Disease
94
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
94
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
399
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
399
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
954
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954